Open AccessEffects of Abciximab, Ticlopidine, and Combined Abciximab/Ticlopidine Therapy on Platelet and Leukocyte Function in Patients Undergoing Coronary Angioplasty
Author(s) -
Becky J. Fredrickson,
Nancy A. Turner,
Neal S. Kleiman,
Nikki Graziadei,
Kelly Maresh,
Mary Ann Mascelli,
Mark B. Effron,
Larry V. McIntire
Publication year - 2000
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.101.10.1122
Subject(s) - abciximab , medicine , ticlopidine , platelet , angioplasty , platelet adhesiveness , cardiology , von willebrand factor , antiplatelet drug , thrombosis , thrombus , pharmacology , anesthesia , surgery , aspirin , percutaneous coronary intervention , myocardial infarction , clopidogrel , platelet aggregation
Abciximab and ticlopidine reduce adverse cardiovascular events after percutaneous transluminal coronary angioplasty (PTCA). The goal of the current study was to determine if combined abciximab/ticlopidine therapy inhibits arterial thrombosis more effectively than either treatment alone. The effect of each therapy on platelet-leukocyte interactions was also investigated.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom